Clinical Trial: Treatment of Hidradenitis Suppurativa Using Etanercept

Study Status: Completed
Recruit Status: Completed
Study Type: Observational

Official Title: Treatment of Hidradenitis Suppirativa With Etanercept Injection

Brief Summary: Therapy with etanercept, a TNF inhibitor will reverse the inflammation, symptoms and quality of life and allow healing of HS.

Detailed Summary:
Sponsor: Penn State University

Current Primary Outcome: Physician global assessment of HS of clear or mild at week 12 [ Time Frame: Week 12 ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Penn State University

Dates:
Date Received: July 29, 2009
Date Started: April 2005
Date Completion:
Last Updated: July 29, 2009
Last Verified: July 2009